ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Biomea Fusion (BMEA)
Biomea Fusion stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.64▲ +1.01%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
41%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Biomea Fusion in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Biomea Fusion
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Biomea Fusion a 41% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.46 and $0.76; in 9 out of 10, between $0.29 and $1.19. Estimated annual volatility is 162%.
Price, last 12 months (weekly close)
Key numbers
- 52-week high
- $2.24
- 52-week low
- $0.55
- Revenue (12 months)
- $0.0M
- Return on equity
- -164.1%
- Free cash flow (12 months)
- $-27.8M
- Beta
- -0.24
What this means
ATLAS does not publish a fair value for BMEA right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks BMEA has traded between $0.55 and $2.24. Today it is 71.3% below that high and 16% above its low.
Its beta is -0.24: it tends to move less than the market.
About the company
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases.
Want to see everything about Biomea Fusion?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does Biomea Fusion do?
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases.
What is the chance BMEA goes up next month?
41%: somewhat worse than a coin flip. In half of the simulated outcomes, BMEA ends the month between $0.46 and $0.76.
How volatile is BMEA?
ATLAS estimates annual volatility at 162%. In a typical month, half of the outcomes end between $0.46 and $0.76.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer